Use of botulinum toxine in the clinical practice
Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S
Record ID 32005000633
Spanish
Authors' objectives:
The aim of this study is to examine the use of botulinum toxine in clinical practice
Authors' results and conclusions:
It is important to consider that botulinum toxine type A (BTA), as therapy, is a palliative treatment (not curative), of transient effect (therefore requiring periodic administration), and relatively expensive. On the other hand, the available studies usually include few patients, and use placebo as comparator when, in many cases there other treatment alternatives. All these greatly limit the possibility of objectively evaluating the role of the botulinum toxine treatment. For these reasons, it is important to assess the potential benefits in a comprehensive therapeutic setting, and not only to verify its efficacy to decrease focal muscular hyperactivity.
Authors' recommendations:
It is important to make a correct patient selection of those who may benefit from this intervention: - Patients with confirmed upper motoneuron syndrome - No contraindications to botulinum toxine therapy - With hypertonia that interferes with function - Without development of fixed contractures - With few affected muscles - Realistic and defined functional endpoints or objectives - Who have failed other therapeutic approaches - Adequate concomitant physical therapy
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.